{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:27:40Z","timestamp":1790537260640,"version":"4.1.0"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Immunomodulating drugs are widely used in autoimmune, transplant, and cancer patients. However, these drugs are associated with various autoimmune neuromuscular diseases such as demyelinating polyneuropathy, myasthenia gravis, and myositis. Early recognition of these complications and immediately terminating these drugs are very essential since some are life-threatening conditions. This review provides a general overview of drug-induced autoimmunity and autoimmune neuromuscular diseases associated with tumor necrosis factor alpha (TNF-\u03b1) antagonists, immune checkpoint inhibitors, and interferon (IFN) type 1 (IFN-\u03b2 and IFN-\u03b1).<\/jats:p>","DOI":"10.1097\/cnd.0000000000000214","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T01:37:18Z","timestamp":1534729038000},"page":"28-34","source":"Crossref","is-referenced-by-count":4,"title":["Autoimmune Neuromuscular Diseases Induced by Immunomodulating Drugs"],"prefix":"10.1097","volume":"20","author":[{"given":"Songkit","family":"Supakornnumporn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Katirji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230905","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1196\/annals.1422.019","article-title":"Drug-induced lupus","volume":"1108","author":"Borchers","year":"2007","journal-title":"Ann N Y Acad Sci."},{"key":"R2-20230905","doi-asserted-by":"crossref","first-page":"9259646","DOI":"10.1155\/2016\/9259646","article-title":"Biologics for targeting inflammatory cytokines, clinical uses, and limitations","volume":"2016","author":"Rider","year":"2016","journal-title":"Int J Cell Biol."},{"key":"R3-20230905","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/rheumatology\/keh439","article-title":"Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy","volume":"44","author":"Rodriguez-Escalera","year":"2005","journal-title":"Rheumatology (Oxford)."},{"key":"R4-20230905","first-page":"2079","article-title":"Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis","volume":"31","author":"Richette","year":"2004","journal-title":"J Rheumatol."},{"key":"R5-20230905","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/mus.21584","article-title":"Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-\u03b1 antagonists","volume":"41","author":"Alshekhlee","year":"2010","journal-title":"Muscle Nerve."},{"key":"R6-20230905","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/art.10488","article-title":"Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al","volume":"46","author":"Cisternas","year":"2002","journal-title":"Arthritis Rheum."},{"key":"R7-20230905","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mus.20924","article-title":"Tumor necrosis factor-alpha antagonists and neuropathy","volume":"37","author":"St\u00fcbgen","year":"2008","journal-title":"Muscle Nerve."},{"key":"R8-20230905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.05.010","article-title":"Drug-induced dysimmune demyelinating neuropathies","volume":"307","author":"St\u00fcbgen","year":"2011","journal-title":"J Neurol Sci."},{"key":"R9-20230905","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","article-title":"Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-\u03b1 agents","volume":"13","author":"Fiorino","year":"2014","journal-title":"Autoimmun Rev."},{"key":"R10-20230905","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1212\/01.WNL.0000147242.92691.71","article-title":"Etanercept treatment in corticosteroid-dependent myasthenia gravis","volume":"63","author":"Rowin","year":"2004","journal-title":"Neurology."},{"key":"R11-20230905","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.autrev.2007.01.001","article-title":"Therapeutic options in autoimmune myasthenia gravis","volume":"6","author":"Garc\u00eda-Carrasco","year":"2007","journal-title":"Autoimmun Rev."},{"key":"R12-20230905","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/mus.21280","article-title":"Myasthenia gravis associated with etanercept therapy","volume":"39","author":"Fee","year":"2009","journal-title":"Muscle Nerve."},{"key":"R13-20230905","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5692\/clinicalneurol.53.351","article-title":"A case of myasthenia gravis following sarcoidosis and rheumatoid arthritis [in Japanese]","volume":"53","author":"Sawada","year":"2013","journal-title":"Rinsho Shinkeigaku."},{"key":"R14-20230905","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/1756-185X.12340","article-title":"Myasthenia gravis onset during rheumatic disease: a new paradoxical effect of anti-TNF alpha therapy?","volume":"18","author":"Bruzzese","year":"2015","journal-title":"Int J Rheum Dis."},{"key":"R15-20230905","doi-asserted-by":"crossref","first-page":"179180","DOI":"10.1155\/2014\/179180","article-title":"New onset of dermatomyositis\/polymyositis during anti-TNF-\u03b1 therapies: a systematic literature review","volume":"2014","author":"Brunasso","year":"2014","journal-title":"ScientificWorldJournal."},{"key":"R16-20230905","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/art.22358","article-title":"Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor","volume":"55","author":"Hall","year":"2006","journal-title":"Arthritis Rheum."},{"key":"R17-20230905","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/keg388","article-title":"Polymyositis associated with infliximab treatment for rheumatoid arthritis","volume":"42","author":"Musial","year":"2003","journal-title":"Rheumatology (Oxford)."},{"key":"R18-20230905","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/s10165-006-0523-1","article-title":"Polymyositis associated with infliximab treatment for rheumatoid arthritis","volume":"16","author":"Urata","year":"2006","journal-title":"Mod Rheumatol."},{"key":"R19-20230905","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-010-1666-1","article-title":"A case of antisynthetase syndrome in a rheumatoid arthritis patient with antiPL-12 antibody following treatment with etanercept","volume":"30","author":"Ishikawa","year":"2011","journal-title":"Clin Rheumatol."},{"key":"R20-20230905","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity."},{"key":"R21-20230905","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00262-011-1012-8","article-title":"Camouflage and sabotage: tumor escape from the immune system","volume":"60","author":"Poschke","year":"2011","journal-title":"Cancer Immunol Immunother."},{"key":"R22-20230905","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr Opin Neurol."},{"key":"R23-20230905","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"R24-20230905","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","article-title":"Neurological immune-related adverse events of ipilimumab","volume":"13","author":"Bot","year":"2013","journal-title":"Pract Neurol."},{"key":"R25-20230905","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","article-title":"A severe case of ipilimumab-induced Guillain-Barr\u00e9 syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis","volume":"36","author":"Gaudy-Marqueste","year":"2013","journal-title":"J Immunother."},{"key":"R26-20230905","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/annonc\/mdr028","article-title":"Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient","volume":"22","author":"Wilgenhof","year":"2011","journal-title":"Ann Oncol."},{"key":"R27-20230905","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-induced demyelinating polyradiculoneuropathy","volume":"375","author":"De Maleissye","year":"2016","journal-title":"N Engl J Med."},{"key":"R28-20230905","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CND.0000000000000193","article-title":"Guillain-Barr\u00e9 syndrome triggered by immune checkpoint inhibitors: a case report and literature review","volume":"19","author":"Supakornnumporn","year":"2016","journal-title":"J Clin Neuromuscul Dis."},{"key":"R29-20230905","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet."},{"key":"R30-20230905","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/jjco\/hyw090","article-title":"Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barr\u00e9 syndrome: a case report","volume":"46","author":"Tanaka","year":"2016","journal-title":"Jpn J Clin Oncol."},{"key":"R31-20230905","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol."},{"key":"R32-20230905","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","article-title":"Myasthenia triggered by immune checkpoint inhibitors: new case and literature review","volume":"27","author":"Gonzalez","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"R33-20230905","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1002\/mus.25496","article-title":"A case of new-onset antibody positive myasthenia gravis in a patient treated with pembrolizumab for melanoma","volume":"55","author":"Alnahhas","year":"2017","journal-title":"Muscle Nerve."},{"key":"R34-20230905","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol."},{"key":"R35-20230905","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1634\/theoncologist.2016-0170","article-title":"A case of nivolumab-induced myositis","volume":"21","author":"Fox","year":"2016","journal-title":"Oncologist."},{"key":"R36-20230905","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci."},{"key":"R37-20230905","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"key":"R38-20230905","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdw126","article-title":"Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma","volume":"27","author":"Vallet","year":"2016","journal-title":"Ann Oncol."},{"key":"R39-20230905","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/annonc\/mdw655","article-title":"Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm","volume":"28","author":"Haddox","year":"2017","journal-title":"Ann Oncol."},{"key":"R40-20230905","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol."},{"key":"R41-20230905","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drug."},{"key":"R42-20230905","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet."},{"key":"R43-20230905","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2008.12.008","article-title":"Interferon alpha and neuromuscular disorders","volume":"207","author":"St\u00fcbgen","year":"2009","journal-title":"J Neuroimmunol."},{"key":"R44-20230905","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/BF01798543","article-title":"Ocular pseudo-myasthenic reaction induced by interferon in an AIDS patient","volume":"69","author":"Riedel","year":"1991","journal-title":"Klin Wochenschr."},{"key":"R45-20230905","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1136\/jnnp.74.9.1267","article-title":"Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia","volume":"74","author":"Nemni","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"R46-20230905","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/mus.10118","article-title":"Exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a Case report and literature review","volume":"25","author":"Boonyapisit","year":"2002","journal-title":"Muscle Nerve."},{"key":"R47-20230905","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/mus.880150805","article-title":"Vasculitic neuropathy in a patient with cryoglobulinemia and anti-MAG IgM monoclonal gammopathy","volume":"15","author":"Thomas","year":"1992","journal-title":"Muscle Nerve."},{"key":"R48-20230905","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0165-5728(96)00191-9","article-title":"T-cell-mediated epineurial vasculitis is and humoral-mediated microangiopathy in cryoglobulinemic neuropathy","volume":"73","author":"Bonetti","year":"1997","journal-title":"J Neuroimmunol."},{"key":"R49-20230905","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/jnnp.60.3.348","article-title":"Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment","volume":"60","author":"Piccolo","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"R50-20230905","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/jnnp.60.3.348-a","article-title":"Development of myasthenia gravis during interferon-alpha treatment for anti-HCV positive chronic hepatitis","volume":"60","author":"Mase","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"R51-20230905","first-page":"980","article-title":"A case of myasthenia gravis which developed myasthenic crisis after alpha-interferon therapy for chronic hepatitis C [in Japanese]","volume":"36","author":"Konishi","year":"1996","journal-title":"Rinsho Shinkeigaku."},{"key":"R52-20230905","first-page":"221","article-title":"Exacerbation of myasthenia gravis during interferon-alpha treatment","volume":"144","author":"Uyama","year":"1996","journal-title":"J Neurol Sci."},{"key":"R53-20230905","first-page":"75","article-title":"Development of myasthenia gravis after interferon alpha therapy","volume":"39","author":"Gurtubay","year":"1999","journal-title":"Electromyogr Clin Neurophysiol."},{"key":"R54-20230905","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s005350170038","article-title":"Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin","volume":"36","author":"Weegink","year":"2001","journal-title":"J Gastroenterol."},{"key":"R55-20230905","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/10799900152434321","article-title":"Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C","volume":"21","author":"Borgia","year":"2001","journal-title":"J Interferon Cytokine Res."},{"key":"R56-20230905","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000109410","article-title":"Development of Myasthenia gravis due to treatment of chronic hepatitis C with a combination of interferon-alpha and ribavirin","volume":"75","author":"Bektas","year":"2007","journal-title":"Digestion."},{"key":"R57-20230905","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0399-8320(07)78340-9","article-title":"Development of a myasthenia crisis during interferon treatment for chronic C hepatitis","volume":"31","author":"Reffet","year":"2007","journal-title":"Gastroenterol Clin Biol."},{"key":"R58-20230905","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3350\/kjhep.2009.15.2.209","article-title":"Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C","volume":"15","author":"Kang","year":"2009","journal-title":"Korean J Hepatol."},{"key":"R59-20230905","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/CND.0b013e318285257f","article-title":"Pegylated interferon induced myasthenia crisis-a case report","volume":"14","author":"Congeni","year":"2013","journal-title":"J Clin Neuromuscul Dis."},{"key":"R60-20230905","doi-asserted-by":"crossref","first-page":"e3782","DOI":"10.1097\/MD.0000000000003782","article-title":"Myasthenia crisis induced by pegylated-interferon in patient with chronic hepatitis C: a case report","volume":"95","author":"Baik","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"R61-20230905","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/01.wnl.0000171858.82527.4c","article-title":"Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis","volume":"65","author":"Ekstein","year":"2005","journal-title":"Neurology."},{"key":"R62-20230905","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/01.WNL.0000064163.94122.EB","article-title":"Contrasting effects of IFN beta and IVIG in children with central and peripheral demyelination","volume":"60","author":"Pirko","year":"2003","journal-title":"Neurology."},{"key":"R63-20230905","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1212\/WNL.49.6.1747-a","article-title":"Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment","volume":"49","author":"Blake","year":"1997","journal-title":"Neurology."},{"key":"R64-20230905","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/jnnp.2003.028233","article-title":"Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment","volume":"75","author":"Dionisiotis","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"R65-20230905","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0022-510X(99)00082-9","article-title":"Exacerbation of myasthenia gravis in a patient after interferon-beta treatment for chronic active hepatitis C","volume":"165","author":"Harada","year":"1999","journal-title":"J Neurol Sci."},{"key":"R66-20230905","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clineuro.2006.10.003","article-title":"Interferon causes no myasthenia in a seropositive patient with multiple sclerosis","volume":"109","author":"Shimizu","year":"2007","journal-title":"Clin Neurol Neurosurg."},{"key":"R67-20230905","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jneuroim.2009.04.015","article-title":"Recombinant interferon-beta therapy and neuromuscular disorders","volume":"212","author":"St\u00fcbgen","year":"2009","journal-title":"J Neuroimmunol."},{"key":"R68-20230905","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00296-014-2984-4","article-title":"Dermatomyositis as a complication of interferon-\u03b1 therapy: a case report and review of the literature","volume":"34","author":"Shiba","year":"2014","journal-title":"Rheumatol Int."},{"key":"R69-20230905","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol."}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00131402-201809000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T23:23:23Z","timestamp":1693956203000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00131402-201809000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000214","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}